Fumio Nishikaku
Directeur/Membre du Conseil chez HuLA immune, Inc.
Postes actifs de Fumio Nishikaku
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
HuLA immune, Inc.
 HuLA immune, Inc. Pharmaceuticals: MajorHealth Technology HuLA immune, Inc. is a Japanese company that provides immune cell therapy for cancer treatment. The company is based in Tokyo, Japan. The text in the company's description appears to be a mix of non-English languages, including British English and Japanese. It was founded in 2017 and the CEO is Yasuhiro Shindo. | Directeur/Membre du Conseil | - | - |
MATRIXOME, Inc.
 MATRIXOME, Inc. Miscellaneous Commercial ServicesCommercial Services MATRIXOME, Inc. is a Japanese regenerative medicine company founded in 2015. The company is based in Osaka, Japan and develops regenerative medicine using laminin E8 fragment technology. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Fumio Nishikaku
Statistiques
Internationale
| Japon | 3 |
Opérationnelle
| Director/Board Member | 2 |
Sectorielle
| Health Technology | 2 |
| Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 2 |
|---|---|
HuLA immune, Inc.
HuLA immune, Inc. Pharmaceuticals: MajorHealth Technology HuLA immune, Inc. is a Japanese company that provides immune cell therapy for cancer treatment. The company is based in Tokyo, Japan. The text in the company's description appears to be a mix of non-English languages, including British English and Japanese. It was founded in 2017 and the CEO is Yasuhiro Shindo. | Health Technology |
MATRIXOME, Inc.
MATRIXOME, Inc. Miscellaneous Commercial ServicesCommercial Services MATRIXOME, Inc. is a Japanese regenerative medicine company founded in 2015. The company is based in Osaka, Japan and develops regenerative medicine using laminin E8 fragment technology. | Commercial Services |
- Bourse
- Insiders
- Fumio Nishikaku
- Expérience
